OMERS ADMINISTRATION Corp Grows Stock Holdings in Qiagen (NYSE:QGEN)

OMERS ADMINISTRATION Corp raised its stake in Qiagen (NYSE:QGEN) by 37.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,400 shares of the company’s stock after buying an additional 3,400 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Qiagen were worth $552,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brown Brothers Harriman & Co. purchased a new position in Qiagen in the 4th quarter valued at approximately $37,000. Geneos Wealth Management Inc. increased its position in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after buying an additional 251 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after buying an additional 526 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock worth $63,000 after buying an additional 835 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its position in shares of Qiagen by 83.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company’s stock worth $70,000 after buying an additional 712 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Trading Up 1.0%

Shares of QGEN opened at $42.65 on Monday. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The company has a market capitalization of $9.48 billion, a PE ratio of 118.76, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The stock has a fifty day moving average of $40.97 and a two-hundred day moving average of $41.81. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The firm had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. During the same period in the prior year, the firm posted $0.44 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, analysts forecast that Qiagen will post 2.26 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on QGEN. Baird R W downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. StockNews.com upgraded Qiagen from a “buy” rating to a “strong-buy” rating in a research report on Thursday. UBS Group lowered their target price on Qiagen from $50.00 to $48.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Finally, Robert W. Baird boosted their price target on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a report on Monday, April 21st. Seven investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus target price of $48.42.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.